Comparison
Magnesium L-Threonate vs Memantine (Namenda)
Magnesium L-Threonate
MIT-developed magnesium that crosses the blood-brain barrier. Shown to enhance synaptic density and reduce 'brain age'.
Memantine (Namenda)
Prescription NMDA receptor antagonist for moderate-to-severe Alzheimer's disease. Reduces glutamate excitotoxicity while preserving normal signaling.
| Field | Magnesium L-Threonate | Memantine (Namenda) |
|---|---|---|
| Category | neuroprotective | neuroprotective |
| Dose range | 1000–2000mg | 5–20mg |
| Half-life | 6h | 70h |
| Onset | – | 180min |
| Evidence | EVIDENCEB | EVIDENCEA |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USOTC | USRx |
| PubMed refs | 90 | 4200 |
The comparison in plain English
Auto-generated from dataMagnesium L-Threonate and Memantine (Namenda) are both in the neuroprotective category respectively. Magnesium L-Threonate MIT-developed magnesium that crosses the blood-brain barrier. Memantine (Namenda) Prescription NMDA receptor antagonist for moderate-to-severe Alzheimer's disease.
Bottom line
Magnesium L-Threonate (evidence B, safety 5/5) has a stronger evidence base than Memantine (Namenda) (evidence A, safety 4/5). Magnesium L-Threonate has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Magnesium L-Threonate if
Magnesium L-Threonate is the better fit when your goal aligns with its mechanism (L-threonate is a sugar-acid carrier that uniquely enables magnesium to cross the blood-brain barrier in meaningful quantities, most oral magnesium forms (oxide, citrate, glycinate) raise serum magnesium but not central magnesium) and the dose range (1000–2000mg) suits your protocol. Half-life is 6h.
Choose Memantine (Namenda) if
Memantine (Namenda) is the better fit when your goal aligns with its mechanism (Uncompetitive NMDA receptor antagonist, blocks the NMDA channel only when it's pathologically over-activated, sparing normal signaling) and the dose range (5–20mg) suits your protocol. Half-life is 70h.